Starsource Multitrade Ltd
The Chemo Pharma Laboratories Limited was established in 1942 and was making Pharmaceuticals and bulk drugs. However due to increased competition, Company disposed the business. Company is in advanced stage of negotiation to diversify and take over a sick company[1]
- Market Cap ₹ 17.2 Cr.
- Current Price ₹ 115
- High / Low ₹ 153 / 75.0
- Stock P/E
- Book Value ₹ 8.60
- Dividend Yield 0.00 %
- ROCE -164 %
- ROE -164 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 13.4 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 27.9%
- Company has a low return on equity of -31.6% over last 3 years.
- Company has high debtors of 337 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
| 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | |
| Operating Profit | -0 | -0 | -0 | -0 | -1 | -0 | -0 | -0 | -0 | -0 | -0 | -12 |
| OPM % | -2,240% | |||||||||||
| 0 | 0 | 6 | 1 | 1 | 1 | 1 | 1 | 0 | 2 | 1 | 0 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | -12 |
| Tax % | 26% | 31% | 12% | 86% | 19% | 16% | 19% | -56% | 38% | 27% | 33% | 0% |
| 0 | 0 | 5 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | -12 | |
| EPS in Rs | 1.87 | 1.47 | 31.20 | 0.67 | 1.40 | 2.80 | 1.67 | 3.73 | 0.33 | 8.00 | 2.27 | -79.00 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -2733% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 32% |
| 3 Years: | 50% |
| 1 Year: | -19% |
| Return on Equity | |
|---|---|
| 10 Years: | -8% |
| 5 Years: | -18% |
| 3 Years: | -32% |
| Last Year: | -164% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Reserves | 4 | 4 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 11 | 12 | -0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
| Total Liabilities | 6 | 6 | 11 | 10 | 10 | 11 | 11 | 12 | 12 | 13 | 13 | 2 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 4 | 0 | 0 |
| 4 | 4 | 11 | 10 | 10 | 11 | 11 | 9 | 9 | 9 | 13 | 2 | |
| Total Assets | 6 | 6 | 11 | 10 | 10 | 11 | 11 | 12 | 12 | 13 | 13 | 2 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0 | -0 | 6 | -2 | -5 | 5 | -0 | -0 | -1 | 1 | -0 | ||
| 0 | 0 | 1 | 1 | 1 | 1 | -0 | 1 | 1 | -1 | 10 | ||
| 0 | 0 | -0 | 1 | 0 | 0 | 2 | -2 | -0 | -0 | -0 | ||
| Net Cash Flow | 0 | 0 | 6 | 1 | -5 | 6 | 1 | -1 | -0 | 0 | 10 | |
| Free Cash Flow | -0 | -0 | 6 | -2 | -5 | 5 | -0 | -0 | -1 | 1 | -0 | |
| CFO/OP | -25% | 206% | -2,615% | 294% | 970% | -1,023% | 94% | 66% | 335% | -468% | 67% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 337 | |||||||||||
| Inventory Days | 0 | |||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 337 | |||||||||||
| Working Capital Days | 875 | |||||||||||
| ROCE % | 8% | 6% | 4% | 8% | 3% | 5% | 3% | 1% | 1% | 13% | 5% | -164% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Benefit Expenses INR (In Thousands) |
|
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9m - Newspaper Publication of extracts of Audited Financial Results for the Fourth Quarter and Year ended on March 31, 2026.
- Result-Audited Financial Result For The Fourth Quarter And Year Ended On March 31, 2026. 20h
-
Board Meeting Outcome for Outcome Of Board Meeting Held On May 29, 2026
20h - Board approved audited standalone Q4 and FY2026 results on May 29, 2026; auditor issued unmodified opinion.
-
Board Meeting Intimation for Considering Audited Financial Results For The Fourth Quarter And Financial Year Ended March 31, 2026 Along With The Auditors Report Thereon.
25 May - Board to meet on May 29, 2026 to approve FY26 audited financial results; trading window closed until 48 hours after results.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
15 Apr - Starsource Multitrade confirms it is outside Large Corporate criteria as of March 31, 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Background[1]
The Chemo Pharma Laboratories Limited was established in 1942 and has been making pharmaceuticals and diversified into bulk drugs. However due to increase in competition and flow of new drugs, Company disposes their business and pay all its liabilities and dues. Presently the Company has its own cash resource, with this the Company is proposing to diversify and to take over Sick Company which has excellent future potential. The Company is in advance in the negotiation to some other company and soon rehab to acquire business in Power and Chemicals.